Equity Profile

RMD

ResMed Inc.

Health CareHealth Care Equipment$32.9B

Aug6Thu

Pre-Earnings Brief

UpcomingQ4-2026After Close5:00 PM EDT

Company Snapshot

ResMed Inc. (RMD) operates in the health care sector, focusing on equipment and software solutions for people with sleep apnea and chronic obstructive pulmonary disease (COPD)....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a crucial indicator of the company's profitability and financial health, which investors closely monitor.

Expected to be around $2.86.

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and meet customer demand, which is vital for long-term success.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RMD Q4-2026 Earnings Preview

Context

Company Snapshot

ResMed Inc. (RMD) operates in the health care sector, focusing on equipment and software solutions for people with sleep apnea and chronic obstructive pulmonary disease (COPD). As a leader in this space, the company is positioned to benefit from the growing demand for respiratory care and sleep health solutions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.72%

Avg Stock Reaction

+0.21%

Last Quarter Recap

In Q3-2026, ResMed reported an EPS of $2.86, exceeding expectations by 2.58%. The stock reacted positively, gaining 0.89% the following day.

Management Promises & Guidance

Continued focus on expanding product offerings in sleep and respiratory care.
Commitment to enhancing digital health solutions.
Plans to increase market penetration in emerging markets.

Expectations

Wall Street Expectations

Overall, analysts expect ResMed to maintain its strong performance, especially given its history of beating EPS estimates. However, concerns about revenue growth and market competition linger.

Bull Case

If ResMed continues to outperform EPS expectations, it could signal robust demand for its products, leading to further stock appreciation.

Bear Case

If the company fails to meet revenue expectations or faces increased competition, it could lead to a decline in investor confidence and stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $2.86.

EPS is a crucial indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

Not available.

Revenue growth reflects the company's ability to expand its market share and meet customer demand, which is vital for long-term success.

Market Share in Sleep Apnea Devices

Not available.

Understanding market share helps gauge competitive positioning and growth potential in a key segment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth rate for the upcoming quarter?

Revenue growth is critical for assessing the company's ability to expand its market presence and meet investor expectations.

How is ResMed addressing competition in the sleep apnea device market?

Understanding competitive strategies will provide insight into ResMed's future performance and market positioning.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating ResMed's ability to capture market share in emerging markets, which could drive unexpected revenue growth.

Supporting Evidence

ResMed's recent product innovations are not fully reflected in current market expectations.

The company's historical performance shows a consistent ability to exceed EPS estimates, indicating potential for upside.

Options pricing suggests a higher expected move than historical averages, indicating market uncertainty.

Key Risk

If revenue growth exceeds expectations, it could significantly alter the market's perception of ResMed's competitive position.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether ResMed can sustain its growth trajectory amid increasing competition and evolving consumer needs.

Bull Confirmed If

Achieving an EPS of $2.90 or higher would confirm strong demand and operational efficiency.

Bear Confirmed If

An EPS below $2.80 could raise concerns about market competitiveness and growth sustainability.

Pre-Earnings Positioning

Options Market

Implied Move

±5.12%

Historical Avg

±0.9%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±5.1% while RMD has averaged ±0.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

31.1%

Calls (4K)P/C Ratio: 0.65Puts (155K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ResMed beats expectations, history suggests the stock could rise by about 0.21%, confirming strong demand and operational strength.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may experience muted movement as investors reassess growth prospects.

Miss

If the company misses expectations, history suggests a potential decline of around 0.54%, which could lead to increased skepticism about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in sleep and respiratory care.
2Insights into market share gains in emerging markets.
3Management's outlook on competition and pricing strategies.
4Details on digital health initiatives and their impact on growth.
5Guidance on revenue expectations for the next quarter.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

ResMed Inc. (RMD) operates in the health care sector, focusing on equipment and software solutions for people with sleep apnea and chronic obstructive pulmonary disease (COPD)....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a crucial indicator of the company's profitability and financial health, which investors closely monitor.

Expected to be around $2.86.

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and meet customer demand, which is vital for long-term success.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RMD Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.72%

Avg Stock Reaction

+0.21%

Last Quarter Recap

In Q3-2026, ResMed reported an EPS of $2.86, exceeding expectations by 2.58%. The stock reacted positively, gaining 0.89% the following day.

Management Promises & Guidance

Continued focus on expanding product offerings in sleep and respiratory care.
Commitment to enhancing digital health solutions.
Plans to increase market penetration in emerging markets.

Expectations

Wall Street Expectations

Overall, analysts expect ResMed to maintain its strong performance, especially given its history of beating EPS estimates. However, concerns about revenue growth and market competition linger.

Bull Case

If ResMed continues to outperform EPS expectations, it could signal robust demand for its products, leading to further stock appreciation.

Bear Case

If the company fails to meet revenue expectations or faces increased competition, it could lead to a decline in investor confidence and stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $2.86.

EPS is a crucial indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

Not available.

Revenue growth reflects the company's ability to expand its market share and meet customer demand, which is vital for long-term success.

Market Share in Sleep Apnea Devices

Not available.

Understanding market share helps gauge competitive positioning and growth potential in a key segment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth rate for the upcoming quarter?

Revenue growth is critical for assessing the company's ability to expand its market presence and meet investor expectations.

How is ResMed addressing competition in the sleep apnea device market?

Understanding competitive strategies will provide insight into ResMed's future performance and market positioning.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating ResMed's ability to capture market share in emerging markets, which could drive unexpected revenue growth.

Supporting Evidence

ResMed's recent product innovations are not fully reflected in current market expectations.

The company's historical performance shows a consistent ability to exceed EPS estimates, indicating potential for upside.

Options pricing suggests a higher expected move than historical averages, indicating market uncertainty.

Key Risk

If revenue growth exceeds expectations, it could significantly alter the market's perception of ResMed's competitive position.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether ResMed can sustain its growth trajectory amid increasing competition and evolving consumer needs.

Bull Confirmed If

Achieving an EPS of $2.90 or higher would confirm strong demand and operational efficiency.

Bear Confirmed If

An EPS below $2.80 could raise concerns about market competitiveness and growth sustainability.

Pre-Earnings Positioning

Options Market

Implied Move

±5.12%

Historical Avg

±0.9%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±5.1% while RMD has averaged ±0.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

31.1%

Calls (4K)P/C Ratio: 0.65Puts (155K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ResMed beats expectations, history suggests the stock could rise by about 0.21%, confirming strong demand and operational strength.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may experience muted movement as investors reassess growth prospects.

Miss

If the company misses expectations, history suggests a potential decline of around 0.54%, which could lead to increased skepticism about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in sleep and respiratory care.
2Insights into market share gains in emerging markets.
3Management's outlook on competition and pricing strategies.
4Details on digital health initiatives and their impact on growth.
5Guidance on revenue expectations for the next quarter.